Sign In
Buy GOVX
$1.32
-0.0200 (-1.49%)
At Close: Jun 22, 2026
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
09:00am, Monday, 29'th Jan 2024
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
09:00am, Monday, 08'th Jan 2024
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company develop
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
09:00am, Thursday, 04'th Jan 2024
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMe
GeoVax Announces Issuance of Malaria Vaccine Patent
09:00am, Wednesday, 03'rd Jan 2024
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology compan
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
09:00am, Wednesday, 27'th Dec 2023
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
09:00am, Tuesday, 19'th Dec 2023
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dis
GeoVax to Participate in Upcoming December Investor Events
09:00am, Wednesday, 29'th Nov 2023
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dis
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
09:00am, Tuesday, 28'th Nov 2023
Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 2
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
09:00am, Tuesday, 14'th Nov 2023
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company d
GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
09:26pm, Wednesday, 08'th Nov 2023
GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
09:00am, Tuesday, 12'th Sep 2023
Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
09:00am, Thursday, 31'st Aug 2023
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
09:00am, Tuesday, 29'th Aug 2023
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
09:00am, Wednesday, 26'th Jul 2023
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology c
GeoVax Labs, Inc. (GOVX) Q1 2023 Earnings Call Transcript
11:25am, Sunday, 07'th May 2023
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gabby DeGravina - Investor Relations David Dodd - Chairman and Chief Executive Officer Mar
